915087-24-0

Basic information

• Product Name: 2-FLUORO-N-METHYL-4-NITROBENZAMIDE
• Synonyms: 2-FLUORO-N-METHYL-4-NITROBENZAMIDE;N-Methyl-2-fluoro-4-nitrobenzamide;BenzaMide, 2-fluoro-N-Methyl-4-nitro-;1. 2-fluoro-N-Methyl-4-nitrobenzaMide;4-Nitro-2-fluoro-N-MethylbenzaMide
• CAS NO: 915087-24-0
• Molecular Formula: C₈H₇FN₂O₃
• Molecular Weight: 198.15
• Product Categories: 2-fluoro-N-methyl-4-nitrobenzamide
• Mol File: 915087-24-0.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Density: 1.358
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-FLUORO-N-METHYL-4-NITROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-N-METHYL-4-NITROBENZAMIDE(915087-24-0)
• EPA Substance Registry System: 2-FLUORO-N-METHYL-4-NITROBENZAMIDE(915087-24-0)

Safety Data

• Hazardous Substances Data: 915087-24-0(Hazardous Substances Data)

Usage

Uses

2-?Fluoro-?N-?methyl-?4-?nitrobenzamide is used in the preparation of androgen receptor antagonists MDV3100. MDV3100 is also a clinical candidate for the treatment of hormone refractory prostrate cancer.

InChI:InChI=1S/C8H9FN2O/c1-11-8(12)6-3-2-5(10)4-7(6)9/h2-4H,10H2,1H3,(H,11,12)

Upstream product

• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 74-89-5 methylamine 
• 1427-07-2 2-fluoro-4-nitrotoluene 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 1161795-40-9 5-(2-Fluoro-4-nitro-phenyl)-1-methyl-1H-tetrazole 
• 915087-26-2 4-(1-cyano-cyclobutanylamino)-2-fluoro-N-methyl-benzamide 
• 915087-32-0 N-methyl-2-fluoro-4-(1,1-dimethyl-cyanomethyl)-aminobenzamide 
• 1245736-64-4 4-[7-(2-chloro-4-cyano-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-42-8 4-[7-(4-cyano-3-methoxy-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-96-3 4-[7-(4-cyano-2,5-difluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-60-0 4-[7-(4-cyano-2-trifluoromethoxy-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-61-1 4-[7-(4-cyano-2-fluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-62-2 4-[7-(4-cyano-2-methyl-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-63-3 4-[7-(4-cyano-2-trifluoromethyl-phenyl)-8-oxo-6-thio-5,7-diazaspiro[3,4]-5-octyl]-2-fluoro-N-methyl benzamide 
• 1272718-97-4 4-[7-(3-chloro-4-cyano-2-fluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-43-9 4-[7-(3,4-dicyano-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-98-5 4-[7-(4-cyano-2-fluoro-3-trifluoromethyl-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-99-6 4-[3-(3-chloro-4-cyano-2-fluoro-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 

Relevant articles and documents

Process for the preparation of 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and its polymorphs

The present application relates a process for the preparation of 4- [7 - (6-Cyano- 5- trifluoro methyl pyridin-3- yl) -8- oxo -6- thioxo- 5,7- diazaspiro [3.4] oct-5- yl]- 2-fluoro-N-methyl benzamide of formula-1. The present application further discloses a processes for the preparation of amorphous and crystalline form of compound of formula-1. Formula-1.

SOLID STATE FORMS OF APALUTAMIDE

Disclosed are solid state forms of Apalutamide and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and o edemas, and also ophthalmic disorders.